Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
From MaRDI portal
Publication:1790751
DOI10.1016/J.JTBI.2013.06.036zbMATH Open1397.92312arXiv1306.4842OpenAlexW2962783505WikidataQ45998827 ScholiaQ45998827MaRDI QIDQ1790751FDOQ1790751
Publication date: 4 October 2018
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Abstract: Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem at the scale of the entire organism of the patient. In silico study of the impact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monotherapy or in combination) is performed to compare a low-dose, continuous, metronomic administration scheme with a more classical maximum tolerated dose schedule. Simulation results reveal differences between primary tumor reduction and control of metastases but overall suggest use of the metronomic protocol.
Full work available at URL: https://arxiv.org/abs/1306.4842
Recommendations
- Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: a mathematical approach
- A review of optimal chemotherapy protocols: from MTD towards metronomic therapy
- A mathematical justification for metronomic chemotherapy in oncology
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Optimizing chemoradiotherapy to target metastatic disease and tumor growth
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- Optimisation of time-scheduled regimen for anti-cancer drug infusion
- On drug resistance and metronomic chemotherapy: a mathematical modeling and optimal control approach
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
Medical applications (general) (92C50) Applications of optimal control and differential games (49N90)
Cites Work
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- A history of the study of solid tumour growth: the contribution of mathematical modelling
- On optimal delivery of combination therapy for tumors
- Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Modeling the impact of anticancer agents on metastatic spreading
- AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem
- A model describing the growth and the size distribution of multiple metastatic tumors
- Synchronisation and control of proliferation in cycling cell population models with age structure
- An age-and-cyclin-structured cell population model for healthy and tumoral tissues
- Role of optimal control theory in cancer chemotherapy
- A model for the resistance of tumor cells to cancer chemotherapeutic agents
- An elementary approach to modeling drug resistance in cancer
- Drug resistance in cancer chemotherapy as an optimal control problem
- The influence of PK/PD on the structure of optimal controls in cancer chemotherapy models
- Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models
- Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular ``pruning
- Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment
- Mathematical and numerical analysis for a model of growing metastatic tumors
- Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
- Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis
- Circadian rhythm and cell population growth
- A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
- Title not available (Why is that?)
Cited In (16)
- PATHO-PHYSIOLOGICALLY BASED LOGISTICS FOR TREATMENT OF CANCER
- Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy
- Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth
- Dynamics and control of a mathematical model for metronomic chemotherapy
- A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications
- Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: a mathematical approach
- Numerical optimal control of a size-structured PDE model for metastatic cancer treatment
- Optimization of an \textit{in vitro} chemotherapy to avoid resistant tumours
- Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases
- Mathematical analysis and simulation study of a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects
- Optimal control of cancer chemotherapy with delays and state constraints
- Why Is Evolution Important in Cancer and What Mathematics Should Be Used to Treat Cancer? Focus on Drug Resistance
- Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer
- Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy
- Game theory for managing evolving systems: challenges and opportunities of including vector-valued strategies and life-history traits
- Practically scheduling hormone therapy for prostate cancer using a mathematical model
This page was built for publication: Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1790751)
